Journal article
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study
- Abstract:
-
Neoadjuvant immune checkpoint blockade (ICB) has shown unprecedented activity in mismatch repair deficient (MMRd) colorectal cancers, but its effectiveness in MMRd endometrial cancer (EC) remains unknown. In this investigator-driven, phase I, feasibility study (NCT04262089), 10 women with MMRd EC of any grade, planned for primary surgery, received two cycles of neoadjuvant pembrolizumab (200 mg IV) every three weeks. A pathologic response (primary objective) was observed in 5/10 patients, wit...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Other, pdf, 150.9MB, Terms of use)
-
(Preview, Other, pdf, 1.2MB, Terms of use)
-
(Preview, Other, pdf, 733.9KB, Terms of use)
-
(Preview, Version of record, pdf, 5.6MB, Terms of use)
-
(Preview, Other, pdf, 82.8KB, Terms of use)
-
- Publisher copy:
- 10.1038/s41467-024-52098-8
Authors
Bibliographic Details
- Publisher:
- Nature Research
- Journal:
- Nature Communications More from this journal
- Volume:
- 15
- Issue:
- 1
- Article number:
- 7695
- Publication date:
- 2024-09-03
- Acceptance date:
- 2024-08-26
- DOI:
- EISSN:
-
2041-1723
Item Description
- Language:
-
English
- Source identifiers:
-
2237752
- Deposit date:
-
2024-09-04
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record